IBOGAINE Act
Key claim: The IBOGAINE Act (H.R. 9559, 119th Congress) was referred to the House Committees on Energy and Commerce, Judiciary, and Veterans’ Affairs for consideration of provisions within each committee’s jurisdiction.
Abstract
(HR9559 · 119th Congress) Latest action (2026-06-30): Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Veterans’ Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Why this matters
The IBOGAINE Act represents an early federal legislative push to address ibogaine — a Schedule I psychedelic with growing interest as a potential treatment for opioid use disorder and PTSD, especially among veterans. Its referral to three committees (Energy and Commerce, Judiciary, Veterans’ Affairs) reflects the intersection of drug scheduling, criminal enforcement, and VA care delivery that any access or research pathway would need to navigate. As an introduced bill without enacted text, it has no immediate effect on patients or providers but is a marker of shifting policy attention toward psychedelic-assisted addiction treatment.